Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ608,5609-0,16
KB682,5684,50,74
PKN73,873,981,09
Msft1,47
Nokia3,93753,9395-2,19
IBM2,03
Daimler AG72,2672,28-0,95
PFE1,03
14.05.2021 1:38:55
Indexy online
AD Index online
select
AD Index online
 

  • 13.05.2021 22:00:00
Cardiovascular (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
35,64 1,34 0,47 290 964
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.05.2021
Popis společnosti
Obecné informace
Název společnostiCardiovascular Systems Inc
TickerCSII
Kmenové akcie:Ordinary Shares
RICCSII.O
ISIN-
Prioritní akciePreferred Shares
Prioritní akciePreferred Shares
Prioritní akciePreferred Shares
Poslední známé roční výsledky30.06.2020
Poslední známé čtvrtletní výsledky31.03.2021
Počet zaměstnanců k 30.06.2020 779
Akcie v oběhu k 29.01.2021 40 191 937
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice1225 Old Highway 8 NW
MěstoST. PAUL
PSČ55112-6416
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 512 591 600
Fax16126773355

Business Summary: Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Financial Summary: BRIEF: For the six months ended 31 December 2020,Cardiovascular Systems Inc revenues decreased 6% to$124.7M. Net loss decreased 77% to $2.1M. Revenues reflectPeripheral Products segment decrease of 7% to $86.9M,Coronary Products segment decrease of 5% to $37.8M, UnitedStates segment decrease of 5% to $120.7M, Internationalsegment decrease of 25% to $4M. Lower net loss reflectsSelling.
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Medical Equipment, Supplies & Distribution - NEC
RBSS2004Medical Equipment, Supplies & Distribution
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICS2007Surgical & Medical Instrument Mfg
NAICS2007Electromedical Apparatus Mfg
NAICS1997Surgical and Medical Instrument Manufacturing
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
SICSurgical And Medical Instruments
SICSurgical And Medical Instruments
SICElectromedical Equipment



  • Poslední aktualizace: 14.05.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerScott Ward6016.08.2016
Chief Financial OfficerJeffrey Points4307.02.2018
Chief Operating OfficerRhonda Robb5224.01.201824.01.2018
Chief Human Resource OfficerStephen Rempe47
Chief Compliance OfficerSandra Sedo56
Vice President - Manufacturing and OperationsJohn Hastings40
Vice President - Corporate Development and Intellectual PropertyDavid Whitescarver62
General Counsel and Corporate SecretaryAlexander Rosenstein48
Chief Medical OfficerRyan Egeland45